Phillygenin inhibits histone lactylation-modified NF-κB to reduce sepsis-induced acute lung injury
Ontology highlight
ABSTRACT: Acute lung injury (ALI) is a life-threatening pulmonary complication of sepsis that presents high morbidity and mortality in clinical settings and creates an urgent need for effective therapies. Phillygenin (PHI), a bioactive compound derived from Forsythia suspensa (a traditional Chinese medicinal herb), exhibits antioxidant and antitumor properties; however, its efficacy and mechanisms against sepsis-induced ALI remain largely unexplored. This study aimed to investigate the protective effects of PHI against sepsis-induced ALI by targeting H3K18 lactylation (H3K18la)/nuclear factor-κB (NF-κB)-mediated pulmonary inflammation and pyroptosis. We used a cecal ligation and puncture mouse model of septic ALI and lipopolysaccharide (LPS)-stimulated MLE12 alveolar epithelial cells for in vivo and in vitro studies. In vitro, PHI treatment downregulated nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing 3 (NLRP3), apoptosis-associated speck-like protein (ASC), tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-18 expression in LPS-stimulated MLE12 cells. PHI also suppressed the pyroptotic executors (GSDMD-N and cleaved-caspase-1) activation and reduced H3K18la levels. In vivo, PHI improved survival rates, attenuated lung histopathological damage, and ameliorated pulmonary edema in ALI mice by inhibiting H3K18la/NF-κB signaling pathway. Mechanistically, PHI attenuated inflammatory responses and pyroptosis in MLE12 cells in vitro and alleviated ALI in C57BL/6 mice by targeting the H3K18la/NF-κB pathway. These results provide novel mechanistic insights into the epigenetic regulation of septic lung injury and identify PHI as a promising therapeutic candidate for ALI.
ORGANISM(S): Mus musculus
PROVIDER: GSE315492 | GEO | 2026/01/05
REPOSITORIES: GEO
ACCESS DATA